prostaglandin E receptor 4 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored PTGER4P2 profile across patient tissues and cancer cell-line models. PTGER4P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, PTGER4P2 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, PTGER4P2 RNA expression shows 14,337 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight UCEC, THCA, and PCPG as cancer lineages where PTGER4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTGER4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTGER4P2 survival associations across molecular data types. PTGER4P2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTGER4P2 RNA expression–survival associations across cancer types. High PTGER4P2 expression shows unfavorable associations in UCEC, ACC and MESO, but favorable associations in KIRC, UCS and BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify UCEC as the clearest survival context for PTGER4P2 RNA expression.
This table summarizes PTGER4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PTGER4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTGER4P2 shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, HNSC, BRCA and LUSC. The THCA box plot shows higher PTGER4P2 RNA expression in normal versus tumor tissue (log2 FC = −1.332, t-test p < 0.001).
This table shows molecular features associated with PTGER4P2 in patient tissues and cancer cell lines. In patient samples, PTGER4P2 shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set.
